Pathologist-in-Chief and Benjamin Castleman Professor of Pathology, Massachusetts General Hospital and Harvard Medical School
Pathology
Dr. David N. Louis, MD
David Louis is an expert in the field of Pathology. He graduated from Stony Brook University School of Medicine. He over the years received 2 awards: "Lead editor" and "Super Doctor". Dr. David N. Louis is a published physician. He has 101 publications published. The most current publication "Molecular background of oligodendroglioma: 1p/19q, IDH, TERT, CIC and FUBP1." He is registered with Medicare.
Publications
- Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets.
- The role of neuropathology in the management of patients with diffuse low grade glioma : A systematic review and evidence-based clinical practice guideline.
- Molecular background of oligodendroglioma: 1p/19q, IDH, TERT, CIC and FUBP1.
- BRAF alteration status and the histone H3F3A gene K27M mutation segregate spinal cord astrocytoma histology.
- Brain tumor cells in circulation are enriched for mesenchymal gene expression.
- Cross-reactivity of the BRAF VE1 antibody with epitopes in axonemal dyneins leads to staining of cilia.
- Computational pathology: an emerging definition.
- Recursive partitioning analysis of prognostic variables in newly diagnosed anaplastic oligodendroglial tumors.
- International Society of Neuropathology-Haarlem Consensus Guidelines, for Nervous System Tumor Classification and Grading.
- Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma.
- VE1 Antibody Immunoreactivity in Normal Anterior Pituitary and Adrenal Cortex Without Detectable BRAF V600E Mutations.
- Reconstructing and Reprogramming the Tumor-Propagating Potential of Glioblastoma Stem-like Cells.
- Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas.
- Next-generation molecular genetics of brain tumours.
- Comparison of 2 monoclonal antibodies for immunohistochemical detection of BRAF V600E mutation in malignant melanoma, pulmonary carcinoma, gastrointestinal carcinoma, ...
- An Aberrant Transcription Factor Network Essential for Wnt Signaling and Stem Cell Maintenance in Glioblastoma.
- BRAF V600E Mutation Identifies a Subset of Low-Grade Diffusely Infiltrating Gliomas in Adults.
- Inertial focusing for tumor antigen-dependent and -independent sorting of rare circulating tumor cells.
- Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations.
- The next step in brain tumor classification: "Let us now praise famous men"... or molecules?
- Diagnostic and therapeutic avenues for glioblastoma: no longer a dead end?
- Prospective, high-throughput molecular profiling of human gliomas.
- Case records of the Massachusetts General Hospital. Case 17-2012. A 54-year-old man with visual-field loss and a mass in the brain.
- A tell-tail sign of chromatin: histone mutations drive pediatric glioblastoma.
- Oncolytic Virus-Mediated Manipulation of DNA Damage Responses: Synergy With Chemotherapy in Killing Glioblastoma Stem Cells.
- Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma.
- Rapid Radiographic and Clinical Improvement After Treatment of a MET-Amplified Recurrent Glioblastoma With a Mesenchymal-Epithelial Transition Inhibitor.
- "Next-generation" pathology and laboratory medicine.
- Ultra high speed whole slide image viewing system.
- Maintenance of primary tumor phenotype and genotype in glioblastoma stem cells.
- The Warrens and other pioneering clinician pathologists of the Massachusetts General Hospital during its early years: an appreciation on the 200th anniversary of the h...
- Concurrent CIC mutations, IDH mutations, and 1p/19q loss distinguish oligodendrogliomas from other cancers.
- International retrospective study of over 1000 adults with anaplastic oligodendroglial tumors.
- Isocitrate dehydrogenase 1 analysis differentiates gangliogliomas from infiltrative gliomas.
- A sensitive and specific diagnostic panel to distinguish diffuse astrocytoma from astrocytosis: chromosome 7 gain with mutant isocitrate dehydrogenase 1 and p53.
- BRAF V600E Mutations Are Common in Pleomorphic Xanthoastrocytoma: Diagnostic and Therapeutic Implications.
- Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma.
- Maternally expressed gene 3, an imprinted noncoding RNA gene, is associated with meningioma pathogenesis and progression.
- A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
- A multigene predictor of outcome in glioblastoma.
- Whole-slide imaging digital pathology as a platform for teleconsultation: a pilot study using paired subspecialist correlations.
- A latent class model with hidden Markov dependence for array CGH data.
- Polysomy for chromosomes 1 and 19 predicts earlier recurrence in anaplastic oligodendrogliomas with concurrent 1p/19q loss.
- Genomic profiling of atypical meningiomas associates gain of 1q with poor clinical outcome.
- Bone involvement predicts poor outcome in atypical meningioma.
- Long-term control of disseminated pleomorphic xanthoastrocytoma with anaplastic features by means of stereotactic irradiation.
- MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate temozolomide resistance.
- Decreased rate of infection in glioblastoma patients with allelic loss of chromosome 10q.
- Bead-based profiling of tyrosine kinase phosphorylation identifies SRC as a potential target for glioblastoma therapy.
- Application of signal processing techniques for estimating regions of copy number variations in human meningioma DNA.
- What drives intense apoptosis resistance and propensity for necrosis in glioblastoma? A role for Bcl2L12 as a multifunctional cell death regulator.
- Bcl2L12-mediated inhibition of effector caspase-3 and caspase-7 via distinct mechanisms in glioblastoma.
- "MGMT for pt mgmt": is methylguanine-DNA methyltransferase testing ready for patient management?
- Deregulation of a STAT3-interleukin 8 signaling pathway promotes human glioblastoma cell proliferation and invasiveness.
- Molecular diagnostic testing in malignant gliomas: a practical update on predictive markers.
- MSH6 inactivation and emergent temozolomide resistance in human glioblastomas.
- Malignant astrocytic glioma: genetics, biology, and paths to treatment.
- Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment.
- Olig2-regulated lineage-restricted pathway controls replication competence in neural stem cells and malignant glioma.
- AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.
- Bcl2L12 inhibits post-mitochondrial apoptosis signaling in glioblastoma.
- Activation of STAT3, MAPK, and AKT in malignant astrocytic gliomas: correlation with EGFR status, tumor grade, and survival.
- Marked genomic differences characterize primary and secondary glioblastoma subtypes and identify two distinct molecular and clinical secondary glioblastoma entities.
- Expression of oligodendroglial and astrocytic lineage markers in diffuse gliomas: use of YKL-40, ApoE, ASCL1, and NKX2-2.
- Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses.
- Case records of the Massachusetts General Hospital. Case 23-2006. A 36-year-old man with numbness in the left [corrected] hand and hypertension.
- Epidermal growth factor receptor mutation testing in the care of lung cancer patients.
- AKT activation in human glioblastomas enhances proliferation via TSC2 and S6 kinase signaling.
- Glioma test array for use with formalin-fixed, paraffin-embedded tissue: array comparative genomic hybridization correlates with loss of heterozygosity and fluorescenc...
- A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy.
- Molecular pathology of malignant gliomas.
- Magnetic resonance imaging characteristics predict epidermal growth factor receptor amplification status in glioblastoma.
- Tissue injury from tricyclic antidepressants used as local anesthetics.
- In situ analysis of integrin and growth factor receptor signaling pathways in human glioblastomas suggests overlapping relationships with focal adhesion kinase activat...
- Histology-based expression profiling yields novel prognostic markers in human glioblastoma.
- Genetic analyses for predictors of radiation response in glioblastoma.
- The prognostic impact of histology and 1p/19q status in anaplastic oligodendroglial tumors.
- Autocrine platelet-derived growth factor-dependent gene expression in glioblastoma cells is mediated largely by activation of the transcription factor sterol regulator...
- Statistical considerations for immunohistochemistry panel development after gene expression profiling of human cancers.
- Pulmonary adenocarcinomas with mutant epidermal growth factor receptors.
- YKL-40 is a differential diagnostic marker for histologic subtypes of high-grade gliomas.
- Neoadjuvant temozolomide followed by complete resection of a 1p- and 19q-deleted anaplastic oligoastrocytoma: case study.
- Loss of p53 sensitizes mice with a mutation in Ccm1 (KRIT1) to development of cerebral vascular malformations.
- A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-Attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent mal...
- Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 33-2004. A 34-year-old man with a seizure and a frontal-lobe brain lesion.
- Atypical extraventricular neurocytoma with oligodendroglioma-like spread and an unusual pattern of chromosome 1p and 19q loss.
- Phase I study pilot arms of radiotherapy and carmustine with temozolomide for anaplastic astrocytoma (Radiation Therapy Oncology Group 9813): implications for studies ...
- Imaging correlates of molecular signatures in oligodendrogliomas.
- Mouse models of human cancers (part 3).
- Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.
- Comparative pathology of nerve sheath tumors in mouse models and humans.
- The oligodendroglial lineage marker OLIG2 is universally expressed in diffuse gliomas.
- The role of the cyclin D1-dependent kinases in ErbB2-mediated breast cancer.
- Mutation analysis of CBL-C and SPRED3 on 19q in human glioblastoma.
- Age-dependent prognostic effects of genetic alterations in glioblastoma.
- Potentiated gene delivery to tumors using herpes simplex virus/Epstein-Barr virus/RV tribrid amplicon vectors.
- Gene expression-based classification of malignant gliomas correlates better with survival than histological classification.
- BCL-6 expression predicts improved survival in patients with primary central nervous system lymphoma.
- Multiple meningiomas: Investigating the molecular basis of sporadic and familial forms.
- Oligodendroglioma: toward molecular definitions in diagnostic neuro-oncology.
Schools
State University of New York Health Science Center At Stony Brook
Albany Med Center
Mass General Hospital
Doctors Specialties
- Neuropathology
- Pathology
Accepted Insurances
Awards
- Lead editor
- Super Doctor
Education
-
Massachusetts General Hospital -
Albany Medical Center -
Stony Brook University School of Medicine
Hospital
-
Massachusetts General Hospital
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1326038753 |
| Last Name Of The Provider | LOUIS |
| First Name Of The Provider | DAVID |
| View All |
Similar Doctors
|
Dr. Christopher M. William, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Peter M. Sadow, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Matthew P. Frosch, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Stefanie H. Freeman, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Hannah C. Kinney, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Jennifer K. Sehn, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. E T. Hedley-Whyte, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Zoltan Nagymanyoki, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Roberto Chiarle, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mamta Gupta, MD |
|
|
Dr. Amal Fadaili, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Tracy L. Challies, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Keith L. Ligon, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mel B. Feany, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Angela I. Ruiz, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Angelo A. Ucci, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Tracie Pham, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Lija Joseph, MD
This Doctor is OpenDoctor Recommended.
|